Literature DB >> 35959361

[Survival of Gastric Cancer in Western Honduras Pilot study: 2002-2012].

Eleazar Enrique Montalván1, Daniela María Montalván1, Samuel Alejandro Urrutia1, Aída Argentina Rodríguez1, Héctor Sandoval2, Pedro Odair Sauceda2, Columba Enedina Rodríguez2, Ana Julia Melgar2, Dagoberto Estévez3, Douglas R Morgan4,5, Karla Patricia Torres2, Ricardo Leonel Domínguez1.   

Abstract

Background: Gastric cancer is the second leading cause of cancer death globally. In Honduras the incidence in the last decade was 39 and 21 per 100,000 inhabitants for men and women, respectively. In 2008 IARC (GLOBOCAN) placed Honduras as the country with the highest incidence of gastric cancer in Latin America.
Methods: A retrospective cohort study of patients diagnosed with gastric cancer at the Hospital de Occidente between 2002-2012 was designed. A sample of 144 patients was selected from a total of 490 to obtain a confidence level of 95%. The data collection was obtained by verbal autopsy. Prognostic factors of survival were analyzed using Cox proportional hazards ratio models (CI: 95%). Outcomes: The male/female ratio was 2.8:1. The mean age was 63.29 years. Overall five-year survival was 9.39%. Among patients receiving dual therapy (surgery and chemotherapy), a statistically significant increase in survival was found (10.42%, p=0.048). Between the proximal (28.95%) and distal (56.58%) locations also a statistically significant difference was observed (p=0.03). There was no statistically significant difference in the macroscopic (Borrmann) and microscopic findings (Lauren). Disscusion: This study represents the first effort to estimate survival of gastric cancer in Honduras. Survival may be linked to the location of the primary lesion and the type of treatment. It is expected to develop studies with greater coverage, to answer these questions.

Entities:  

Keywords:  Stomach Neoplasm; Survivorship

Year:  2017        PMID: 35959361      PMCID: PMC9364809     

Source DB:  PubMed          Journal:  Rev Med Hondur        ISSN: 0375-1112


  22 in total

1.  Outcome of pylorus-preserving gastrectomy for early gastric cancer.

Authors:  S Morita; H Katai; M Saka; T Fukagawa; T Sano; M Sasako
Journal:  Br J Surg       Date:  2008-09       Impact factor: 6.939

Review 2.  Adjuvant treatment in gastric cancer.

Authors:  O Agboola
Journal:  Cancer Treat Rev       Date:  1994-07       Impact factor: 12.111

3.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

4.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

5.  Changing patterns in gastric adenocarcinoma.

Authors:  G H Kampschöer; T Nakajima; C J van de Velde
Journal:  Br J Surg       Date:  1989-09       Impact factor: 6.939

6.  Survival benefit of pylorus-preserving gastrectomy in early gastric cancer.

Authors:  Naoki Hiki; Takeshi Sano; Tetsu Fukunaga; Shigekazu Ohyama; Masanori Tokunaga; Toshiharu Yamaguchi
Journal:  J Am Coll Surg       Date:  2009-07-24       Impact factor: 6.113

Review 7.  Epidemiology of gastric cancer.

Authors:  Katherine D Crew; Alfred I Neugut
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

8.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites.

Authors:  J Powell; C C McConkey
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

9.  Case-control study of gastric cancer screening in Venezuela.

Authors:  P Pisani; W E Oliver; D M Parkin; N Alvarez; J Vivas
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Improvements in diagnosis have changed the incidence of histological types in advanced gastric cancer.

Authors:  Y Ikeda; M Mori; T Kamakura; Y Haraguchi; M Saku; K Sugimachi
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.